- Home
- GNLN vs NXTC Comparison
GNLN vs NXTC Comparison
Compare GNLN & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLN
- NXTC
- Stock Information
- Founded
- GNLN 2005
- NXTC 2015
- Country
- GNLN United States
- NXTC United States
- Employees
- GNLN N/A
- NXTC N/A
- Industry
- GNLN Durable Goods
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- GNLN Consumer Discretionary
- NXTC Health Care
- Exchange
- GNLN Nasdaq
- NXTC Nasdaq
- Market Cap
- GNLN 12.9M
- NXTC 13.0M
- IPO Year
- GNLN 2019
- NXTC 2019
- Fundamental
- Price
- GNLN $3.75
- NXTC $5.66
- Analyst Decision
- GNLN
- NXTC Strong Buy
- Analyst Count
- GNLN 0
- NXTC 2
- Target Price
- GNLN N/A
- NXTC $25.50
- AVG Volume (30 Days)
- GNLN 89.4K
- NXTC 13.0K
- Earning Date
- GNLN 11-14-2025
- NXTC 11-06-2025
- Dividend Yield
- GNLN N/A
- NXTC N/A
- EPS Growth
- GNLN N/A
- NXTC N/A
- EPS
- GNLN N/A
- NXTC N/A
- Revenue
- GNLN $7,954,000.00
- NXTC N/A
- Revenue This Year
- GNLN $1,541.21
- NXTC N/A
- Revenue Next Year
- GNLN N/A
- NXTC N/A
- P/E Ratio
- GNLN N/A
- NXTC N/A
- Revenue Growth
- GNLN N/A
- NXTC N/A
- 52 Week Low
- GNLN $2.84
- NXTC $2.69
- 52 Week High
- GNLN $5,130.00
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- GNLN 52.27
- NXTC 62.52
- Support Level
- GNLN $3.35
- NXTC $5.19
- Resistance Level
- GNLN $3.90
- NXTC $5.90
- Average True Range (ATR)
- GNLN 0.25
- NXTC 0.29
- MACD
- GNLN 0.10
- NXTC 0.07
- Stochastic Oscillator
- GNLN 80.00
- NXTC 78.46
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.